Cytek Biosciences Inc. Common Stock (CTKB)

FairStock Score: 40/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses with durable earnings power and a margin of safety. Cytek makes cell-analysis instruments, a technically demanding field. The filed figures show a company that has grown revenue but lost its profitability. Revenue rose from $193.0M in FY2023 to $200.5M in FY2024 and $201.5M in FY2025. That is slow growth, and FairStock's revenue growth figure is 5.57%. More alarming, net income went from a loss of $6.0M in FY2024 to a loss of $66.5M in FY2025. In the latest reported quarter, fiscal Q2 2026 ended 2026-06-30, revenue was $48.1M and net loss was $12.2M. Fiscal Q1 2026 ended 2026-03-31 had revenue of $44.1M and a net loss of $18.9M. The sequential narrowing is a small positive, but the company is still burning cash: trailing free cash flow was -$12.2M, a FairStock FCF yield of -1.8%. The balance sheet offers some comfort. Debt to equity is only 0.08, and the Altman Z-Score is 3.73. The Piotroski F-Score is 6/9. At the 2026-10-13 close of $5.35, market cap was $695.4M; FairStock shows P/B of 2.16, P/E of -8.49, ROE of -23.04%, and ROCE of -6.31%. Lynch's rules call this a TURNAROUND because of a loss in the latest year after earlier profits. As a Graham-style investor, I see no asset bargain at 2.16 times book and no demonstrated earnings power. I would need evidence that losses are shrinking and cash flow is turning positive before calling the price attractive.

In plain English: Cytek makes cell analysis tools for biomedical research and clinical labs. The business looks weak right now: it lost money in fiscal 2025 and in the latest quarter, and it brought in less cash than it spent over the last year. The stock price looks fair to expensive for a company with those losses, even though the company has very little debt.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer